17.9 C
New York
Wednesday, June 3, 2026

Tag: safety

newssourceFORcompanyinformationcontent1marketreleases

Vodafone Business and Geely Technology Europe Extend Partnership to Drive Vehicle Innovation

SINGAPORE and LONDON, June 3, 2026 /PRNewswire/ -- Vodafone Business and Geely Technology Europe (GTEU), the European R&D organisation within Geely Auto Group, have extended...

Levicept to Present Data Suggesting LEVI-04 May Modify Disease in Osteoarthritis at EULAR 2026

Further clinical efficacy and pharmacology data also to be presented 
Further clinical efficacy and pharmacology data also to be presented

Trina Storage Signs 160 MWh Utility-Scale Energy Storage Project in Kyushu, Japan

TOKYO, June 3, 2026 /PRNewswire/ -- Trina Storage, the energy storage business unit of Trinasolar, has signed a contract for a 160 MWh ultra-high...

Autoliv Strengthens Global Safety Innovation

VÅRGÅRDA, Sweden, June 3, 2026 /PRNewswire/ -- Autoliv, Inc. (NYSE: ALV) (SSE: ALIVsdb), the worldwide leader in automotive safety systems, is taking a significant step...

Regulatory release no. 1 – 2026: Publication of Offering Circular and offer price for the Initial Public Offering and admission of the shares of...

3 June 2026

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

Novo Nordisk is launching Wegovy® pill in the UAE, the first country outside the US, to make the Wegovy® pill available to people living with obesity

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and...

ASCO 2026 | Updated Data from an Oral Presentation of InnoCare’s Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released

InnoCare's novel BCL2i mesutoclax in MDS and AML was released at 2026 ASCO as an oral presentation, demonstrating outstanding efficacy and safety.

Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026

CHENGDU, China, June 3, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 American Society...

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with...

Châtillon, France, June 2, 2026

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026...

- The INDIGO study met its primary and all key secondary endpoints with statistically significant results -

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IMMP

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts (“ADRs”) of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive (the “Class Period”), of the important July 6, 2026 lead plaintiff deadline.

Lotus opens orders for Eletre X in mainland Europe

Eletre X is built for drivers who refuse to compromise - delivering ultimate performance, 1,200+ km of range, and 9-minute charging in a practical hybrid SUV.1
Available to order today, starting from €96,990.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSafety

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers